{
    "info": {
        "nct_id": "NCT03276572",
        "official_title": "Phase I Dose-Escalation Trial of 225Ac-J591 in Patients With Metastatic Castration-Resistant Prostate Cancer",
        "inclusion_criteria": "1. Histologically or cytologically confirmed adenocarcinoma of prostate\n2. Documented progressive metastatic CRPC based on Prostate Cancer Working Group 3 (PCWG3) criteria, which includes at least one of the following criteria:\n\n   1. PSA progression\n   2. Objective radiographic progression in soft tissue\n   3. New bone lesions\n3. ECOG performance status of 0-2\n4. Have serum testosterone < 50 ng/dL. Subjects must continue primary androgen deprivation with an LHRH analogue (agonist/antagonist) if they have not undergone bilateral orchiectomy.\n5. Have previously been treated with at least one of the following:\n\n   1. Androgen receptor signaling inhibitor (such as enzalutamide)\n   2. CYP 17 inhibitor (such as abiraterone acetate)\n6. Have previously received taxane chemotherapy, been determined to be ineligible for taxane chemotherapy by their physician, or refused taxane chemotherapy.\n7. Age > 18 years\n8. Patients must have normal organ and marrow function as defined below:\n\n   1. Absolute neutrophil count >2,000 cells/mm3\n   2. Hemoglobin ≥9 g/dL\n   3. Platelet count >150,000 x 109/microliter\n   4. Serum creatinine <1.5 x upper limit of normal (ULN) or calculated creatinine clearance ≥ 60 mL/min/1.73 m2 by Cockcroft-Gault\n   5. Serum total bilirubin <1.5 x ULN (unless due to Gilbert's syndrome in which case direct bilirubin must be normal\n   6. Serum AST and ALT <3 x ULN in absence of liver metastases; <5x ULN if due to liver metastases (in both circumstances, bilirubin must meet entry criteria)\n9. Ability to understand and the willingness to sign a written informed consent document.\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
        "exclusion_criteria": "1. Implantation of investigational medical device ≤4 weeks of Cycle 1, Day 1 or current enrollment in oncologic investigational drug or device study\n2. Use of investigational drugs ≤4 weeks or <5 half-lives of Cycle 1, Day 1 or current enrollment in investigational oncology drug or device study\n3. Prior systemic beta-emitting bone-seeking radioisotopes\n4. Known active brain metastases or leptomeningeal disease\n5. History of deep vein thrombosis and/or pulmonary embolus within 1 month of C1D1\n6. Other serious illness(es) involving the cardiac, respiratory, CNS, renal, hepatic or hematological organ systems which might preclude completion of this study or interfere with determination of causality of any adverse effects experienced in this study\n7. Radiation therapy for treatment of PC ≤4 weeks of Day 1 Cycle 1\n8. Patients on stable dose of bisphosphonates or Denosumab, which have been started no less than 4 weeks prior to treatment start, may continue on this medication, however patients are not allowed to initiate bisphosphonate/Denosumab therapy during the DLT-assessment period of the study.\n9. Having partners of childbearing potential and not willing to use a method of birth control deemed acceptable by the principle investigator and chairperson during the study and for 1 month after last study drug administration\n10. Currently active other malignancy other than non-melanoma skin cancer. Patients are considered not to have \"currently active\" malignancy if they have completed any necessary therapy and are considered by their physician to be at less than 30% risk of relapse.\n11. Known history of known myelodysplastic syndrome",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "identified_line": {
                "line": "8. Patients must have normal organ and marrow function as defined below:",
                "criterions": [
                    {
                        "exact_snippets": "Patients must have normal organ and marrow function",
                        "criterion": "organ and marrow function",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": "normal"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Patients must have normal organ and marrow function",
                        "criterion": "organ and marrow function",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": "normal"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "5. Have previously been treated with at least one of the following:",
                "criterions": [
                    {
                        "exact_snippets": "Have previously been treated with at least one of the following",
                        "criterion": "prior treatment",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "treatment(s)"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Have previously been treated with at least one of the following",
                        "criterion": "prior treatment",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "treatment(s)"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "1. Androgen receptor signaling inhibitor (such as enzalutamide)",
                "criterions": [
                    {
                        "exact_snippets": "Androgen receptor signaling inhibitor (such as enzalutamide)",
                        "criterion": "androgen receptor signaling inhibitor",
                        "requirement": {
                            "requirement_type": "use or exposure",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Androgen receptor signaling inhibitor (such as enzalutamide)",
                        "criterion": "androgen receptor signaling inhibitor",
                        "requirement": {
                            "requirement_type": "use or exposure",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "3. New bone lesions",
                "criterions": [
                    {
                        "exact_snippets": "New bone lesions",
                        "criterion": "bone lesions",
                        "requirement": {
                            "requirement_type": "new occurrence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "New bone lesions",
                        "criterion": "bone lesions",
                        "requirement": {
                            "requirement_type": "new occurrence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. Objective radiographic progression in soft tissue",
                "criterions": [
                    {
                        "exact_snippets": "Objective radiographic progression in soft tissue",
                        "criterion": "soft tissue disease",
                        "requirement": {
                            "requirement_type": "progression",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Objective radiographic progression in soft tissue",
                        "criterion": "soft tissue disease",
                        "requirement": {
                            "requirement_type": "assessment_method",
                            "expected_value": "objective radiographic"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Objective radiographic progression in soft tissue",
                        "criterion": "soft tissue disease",
                        "requirement": {
                            "requirement_type": "progression",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Objective radiographic progression in soft tissue",
                        "criterion": "soft tissue disease",
                        "requirement": {
                            "requirement_type": "assessment_method",
                            "expected_value": "objective radiographic"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "6. Have previously received taxane chemotherapy, been determined to be ineligible for taxane chemotherapy by their physician, or refused taxane chemotherapy.",
                "criterions": [
                    {
                        "exact_snippets": "Have previously received taxane chemotherapy",
                        "criterion": "taxane chemotherapy",
                        "requirement": {
                            "requirement_type": "prior receipt",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "been determined to be ineligible for taxane chemotherapy by their physician",
                        "criterion": "taxane chemotherapy",
                        "requirement": {
                            "requirement_type": "ineligibility (physician determined)",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "refused taxane chemotherapy",
                        "criterion": "taxane chemotherapy",
                        "requirement": {
                            "requirement_type": "refusal",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Have previously received taxane chemotherapy",
                        "criterion": "taxane chemotherapy",
                        "requirement": {
                            "requirement_type": "prior receipt",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "been determined to be ineligible for taxane chemotherapy by their physician",
                        "criterion": "taxane chemotherapy",
                        "requirement": {
                            "requirement_type": "ineligibility (physician determined)",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "refused taxane chemotherapy",
                        "criterion": "taxane chemotherapy",
                        "requirement": {
                            "requirement_type": "refusal",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "9. Ability to understand and the willingness to sign a written informed consent document.",
                "criterions": [
                    {
                        "exact_snippets": "Ability to understand",
                        "criterion": "cognitive ability to understand",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "willingness to sign a written informed consent document",
                        "criterion": "willingness to sign informed consent",
                        "requirement": {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Ability to understand",
                        "criterion": "cognitive ability to understand",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "willingness to sign a written informed consent document",
                        "criterion": "willingness to sign informed consent",
                        "requirement": {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. CYP 17 inhibitor (such as abiraterone acetate)",
                "criterions": [
                    {
                        "exact_snippets": "CYP 17 inhibitor (such as abiraterone acetate)",
                        "criterion": "CYP 17 inhibitor",
                        "requirement": {
                            "requirement_type": "use or exposure",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "CYP 17 inhibitor (such as abiraterone acetate)",
                        "criterion": "CYP 17 inhibitor",
                        "requirement": {
                            "requirement_type": "use or exposure",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Healthy volunteers allowed",
                "criterions": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "1. Absolute neutrophil count >2,000 cells/mm3",
                "criterions": [
                    {
                        "exact_snippets": "Absolute neutrophil count >2,000 cells/mm3",
                        "criterion": "absolute neutrophil count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 2000,
                                "unit": "cells/mm3"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Absolute neutrophil count >2,000 cells/mm3",
                        "criterion": "absolute neutrophil count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 2000,
                                "unit": "cells/mm3"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "3. Platelet count >150,000 x 109/microliter",
                "criterions": [
                    {
                        "exact_snippets": "Platelet count >150,000 x 109/microliter",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 150000,
                                "unit": "x 10^9/microliter"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Platelet count >150,000 x 109/microliter",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 150000,
                                "unit": "x 10^9/microliter"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "1. PSA progression",
                "criterions": [
                    {
                        "exact_snippets": "PSA progression",
                        "criterion": "PSA progression",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "PSA progression",
                        "criterion": "PSA progression",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. Hemoglobin ≥9 g/dL",
                "criterions": [
                    {
                        "exact_snippets": "Hemoglobin ≥9 g/dL",
                        "criterion": "hemoglobin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9,
                                "unit": "g/dL"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Hemoglobin ≥9 g/dL",
                        "criterion": "hemoglobin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9,
                                "unit": "g/dL"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. Documented progressive metastatic CRPC based on Prostate Cancer Working Group 3 (PCWG3) criteria, which includes at least one of the following criteria:",
                "criterions": [
                    {
                        "exact_snippets": "Documented progressive metastatic CRPC",
                        "criterion": "progressive metastatic castration-resistant prostate cancer (CRPC)",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Documented progressive metastatic CRPC",
                        "criterion": "progressive metastatic castration-resistant prostate cancer (CRPC)",
                        "requirement": {
                            "requirement_type": "progression_status",
                            "expected_value": "progressive"
                        }
                    },
                    {
                        "exact_snippets": "Documented progressive metastatic CRPC",
                        "criterion": "progressive metastatic castration-resistant prostate cancer (CRPC)",
                        "requirement": {
                            "requirement_type": "metastatic_status",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Documented progressive metastatic CRPC",
                        "criterion": "progressive metastatic castration-resistant prostate cancer (CRPC)",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Documented progressive metastatic CRPC",
                        "criterion": "progressive metastatic castration-resistant prostate cancer (CRPC)",
                        "requirement": {
                            "requirement_type": "progression_status",
                            "expected_value": "progressive"
                        }
                    },
                    {
                        "exact_snippets": "Documented progressive metastatic CRPC",
                        "criterion": "progressive metastatic castration-resistant prostate cancer (CRPC)",
                        "requirement": {
                            "requirement_type": "metastatic_status",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "3. ECOG performance status of 0-2",
                "criterions": [
                    {
                        "exact_snippets": "ECOG performance status of 0-2",
                        "criterion": "ECOG performance status",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "ECOG performance status of 0-2",
                        "criterion": "ECOG performance status",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "7. Age > 18 years",
                "criterions": [
                    {
                        "exact_snippets": "Age > 18 years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Age > 18 years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "6. Serum AST and ALT <3 x ULN in absence of liver metastases; <5x ULN if due to liver metastases (in both circumstances, bilirubin must meet entry criteria)",
                "criterions": [
                    {
                        "exact_snippets": "Serum AST ... <3 x ULN in absence of liver metastases; <5x ULN if due to liver metastases",
                        "criterion": "serum AST",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<",
                                        "value": 3,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "Serum AST ... <3 x ULN in absence of liver metastases; <5x ULN if due to liver metastases",
                        "criterion": "serum AST",
                        "requirement": {
                            "requirement_type": "context",
                            "expected_value": "in absence of liver metastases"
                        }
                    },
                    {
                        "exact_snippets": "Serum AST ... <3 x ULN in absence of liver metastases; <5x ULN if due to liver metastases",
                        "criterion": "serum AST",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<",
                                        "value": 5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "Serum AST ... <3 x ULN in absence of liver metastases; <5x ULN if due to liver metastases",
                        "criterion": "serum AST",
                        "requirement": {
                            "requirement_type": "context",
                            "expected_value": "if due to liver metastases"
                        }
                    },
                    {
                        "exact_snippets": "ALT <3 x ULN in absence of liver metastases; <5x ULN if due to liver metastases",
                        "criterion": "ALT",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<",
                                        "value": 3,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "ALT <3 x ULN in absence of liver metastases; <5x ULN if due to liver metastases",
                        "criterion": "ALT",
                        "requirement": {
                            "requirement_type": "context",
                            "expected_value": "in absence of liver metastases"
                        }
                    },
                    {
                        "exact_snippets": "ALT <3 x ULN in absence of liver metastases; <5x ULN if due to liver metastases",
                        "criterion": "ALT",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<",
                                        "value": 5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "ALT <3 x ULN in absence of liver metastases; <5x ULN if due to liver metastases",
                        "criterion": "ALT",
                        "requirement": {
                            "requirement_type": "context",
                            "expected_value": "if due to liver metastases"
                        }
                    },
                    {
                        "exact_snippets": "in both circumstances, bilirubin must meet entry criteria",
                        "criterion": "bilirubin",
                        "requirement": {
                            "requirement_type": "meets entry criteria",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "or_criteria": [
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "Serum AST ... <3 x ULN in absence of liver metastases; <5x ULN if due to liver metastases",
                                        "criterion": "serum AST",
                                        "requirement": {
                                            "requirement_type": "quantity",
                                            "expected_value": {
                                                "comparisons": [
                                                    {
                                                        "operator": "<",
                                                        "value": 3,
                                                        "unit": "x ULN"
                                                    }
                                                ]
                                            }
                                        }
                                    },
                                    {
                                        "exact_snippets": "Serum AST ... <3 x ULN in absence of liver metastases; <5x ULN if due to liver metastases",
                                        "criterion": "serum AST",
                                        "requirement": {
                                            "requirement_type": "context",
                                            "expected_value": "in absence of liver metastases"
                                        }
                                    },
                                    {
                                        "exact_snippets": "ALT <3 x ULN in absence of liver metastases; <5x ULN if due to liver metastases",
                                        "criterion": "ALT",
                                        "requirement": {
                                            "requirement_type": "quantity",
                                            "expected_value": {
                                                "comparisons": [
                                                    {
                                                        "operator": "<",
                                                        "value": 3,
                                                        "unit": "x ULN"
                                                    }
                                                ]
                                            }
                                        }
                                    },
                                    {
                                        "exact_snippets": "ALT <3 x ULN in absence of liver metastases; <5x ULN if due to liver metastases",
                                        "criterion": "ALT",
                                        "requirement": {
                                            "requirement_type": "context",
                                            "expected_value": "in absence of liver metastases"
                                        }
                                    }
                                ]
                            },
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "Serum AST ... <3 x ULN in absence of liver metastases; <5x ULN if due to liver metastases",
                                        "criterion": "serum AST",
                                        "requirement": {
                                            "requirement_type": "quantity",
                                            "expected_value": {
                                                "comparisons": [
                                                    {
                                                        "operator": "<",
                                                        "value": 5,
                                                        "unit": "x ULN"
                                                    }
                                                ]
                                            }
                                        }
                                    },
                                    {
                                        "exact_snippets": "Serum AST ... <3 x ULN in absence of liver metastases; <5x ULN if due to liver metastases",
                                        "criterion": "serum AST",
                                        "requirement": {
                                            "requirement_type": "context",
                                            "expected_value": "if due to liver metastases"
                                        }
                                    },
                                    {
                                        "exact_snippets": "ALT <3 x ULN in absence of liver metastases; <5x ULN if due to liver metastases",
                                        "criterion": "ALT",
                                        "requirement": {
                                            "requirement_type": "quantity",
                                            "expected_value": {
                                                "comparisons": [
                                                    {
                                                        "operator": "<",
                                                        "value": 5,
                                                        "unit": "x ULN"
                                                    }
                                                ]
                                            }
                                        }
                                    },
                                    {
                                        "exact_snippets": "ALT <3 x ULN in absence of liver metastases; <5x ULN if due to liver metastases",
                                        "criterion": "ALT",
                                        "requirement": {
                                            "requirement_type": "context",
                                            "expected_value": "if due to liver metastases"
                                        }
                                    }
                                ]
                            }
                        ]
                    },
                    {
                        "exact_snippets": "in both circumstances, bilirubin must meet entry criteria",
                        "criterion": "bilirubin",
                        "requirement": {
                            "requirement_type": "meets entry criteria",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "4. Have serum testosterone < 50 ng/dL. Subjects must continue primary androgen deprivation with an LHRH analogue (agonist/antagonist) if they have not undergone bilateral orchiectomy.",
                "criterions": [
                    {
                        "exact_snippets": "serum testosterone < 50 ng/dL",
                        "criterion": "serum testosterone",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 50,
                                "unit": "ng/dL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Subjects must continue primary androgen deprivation with an LHRH analogue (agonist/antagonist) if they have not undergone bilateral orchiectomy",
                        "criterion": "primary androgen deprivation with an LHRH analogue",
                        "requirement": {
                            "requirement_type": "continuation",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Subjects must continue primary androgen deprivation with an LHRH analogue (agonist/antagonist) if they have not undergone bilateral orchiectomy",
                        "criterion": "primary androgen deprivation with an LHRH analogue",
                        "requirement": {
                            "requirement_type": "applicability",
                            "expected_value": "if no bilateral orchiectomy"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "serum testosterone < 50 ng/dL",
                        "criterion": "serum testosterone",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 50,
                                "unit": "ng/dL"
                            }
                        }
                    },
                    {
                        "condition": {
                            "exact_snippets": "Subjects must continue primary androgen deprivation with an LHRH analogue (agonist/antagonist) if they have not undergone bilateral orchiectomy",
                            "criterion": "primary androgen deprivation with an LHRH analogue",
                            "requirement": {
                                "requirement_type": "applicability",
                                "expected_value": "if no bilateral orchiectomy"
                            }
                        },
                        "then_criteria": {
                            "exact_snippets": "Subjects must continue primary androgen deprivation with an LHRH analogue (agonist/antagonist) if they have not undergone bilateral orchiectomy",
                            "criterion": "primary androgen deprivation with an LHRH analogue",
                            "requirement": {
                                "requirement_type": "continuation",
                                "expected_value": true
                            }
                        },
                        "else_criteria": null
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Must be MALE",
                "criterions": [
                    {
                        "exact_snippets": "Must be MALE",
                        "criterion": "sex",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": "male"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Must be MALE",
                        "criterion": "sex",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": "male"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Must have minimum age of 18 Years",
                "criterions": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            }
        }
    ],
    "exclusion_lines": [
        {
            "identified_line": {
                "line": "11. Known history of known myelodysplastic syndrome",
                "criterions": [
                    {
                        "exact_snippets": "Known history of known myelodysplastic syndrome",
                        "criterion": "myelodysplastic syndrome",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Known history of known myelodysplastic syndrome",
                        "criterion": "myelodysplastic syndrome",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "3. Prior systemic beta-emitting bone-seeking radioisotopes",
                "criterions": [
                    {
                        "exact_snippets": "Prior systemic beta-emitting bone-seeking radioisotopes",
                        "criterion": "prior systemic beta-emitting bone-seeking radioisotope therapy",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Prior systemic beta-emitting bone-seeking radioisotopes",
                    "criterion": "prior systemic beta-emitting bone-seeking radioisotope therapy",
                    "requirement": {
                        "requirement_type": "history",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "4. Known active brain metastases or leptomeningeal disease",
                "criterions": [
                    {
                        "exact_snippets": "Known active brain metastases",
                        "criterion": "brain metastases",
                        "requirement": {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    },
                    {
                        "exact_snippets": "Known active brain metastases",
                        "criterion": "brain metastases",
                        "requirement": {
                            "requirement_type": "knowledge status",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "leptomeningeal disease",
                        "criterion": "leptomeningeal disease",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Known active brain metastases",
                                "criterion": "brain metastases",
                                "requirement": {
                                    "requirement_type": "activity status",
                                    "expected_value": "active"
                                }
                            },
                            {
                                "exact_snippets": "Known active brain metastases",
                                "criterion": "brain metastases",
                                "requirement": {
                                    "requirement_type": "knowledge status",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "leptomeningeal disease",
                        "criterion": "leptomeningeal disease",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "5. History of deep vein thrombosis and/or pulmonary embolus within 1 month of C1D1",
                "criterions": [
                    {
                        "exact_snippets": "History of deep vein thrombosis ... within 1 month of C1D1",
                        "criterion": "deep vein thrombosis",
                        "requirement": {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "month from C1D1"
                            }
                        }
                    },
                    {
                        "exact_snippets": "History of ... pulmonary embolus within 1 month of C1D1",
                        "criterion": "pulmonary embolus",
                        "requirement": {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "month from C1D1"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "History of deep vein thrombosis ... within 1 month of C1D1",
                        "criterion": "deep vein thrombosis",
                        "requirement": {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "month from C1D1"
                            }
                        }
                    },
                    {
                        "exact_snippets": "History of ... pulmonary embolus within 1 month of C1D1",
                        "criterion": "pulmonary embolus",
                        "requirement": {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "month from C1D1"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "7. Radiation therapy for treatment of PC ≤4 weeks of Day 1 Cycle 1",
                "criterions": [
                    {
                        "exact_snippets": "Radiation therapy for treatment of PC ≤4 weeks of Day 1 Cycle 1",
                        "criterion": "radiation therapy for treatment of prostate cancer (PC)",
                        "requirement": {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Radiation therapy for treatment of PC ≤4 weeks of Day 1 Cycle 1",
                        "criterion": "radiation therapy for treatment of prostate cancer (PC)",
                        "requirement": {
                            "requirement_type": "reference timepoint",
                            "expected_value": "Day 1 Cycle 1"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Radiation therapy for treatment of PC ≤4 weeks of Day 1 Cycle 1",
                        "criterion": "radiation therapy for treatment of prostate cancer (PC)",
                        "requirement": {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Radiation therapy for treatment of PC ≤4 weeks of Day 1 Cycle 1",
                        "criterion": "radiation therapy for treatment of prostate cancer (PC)",
                        "requirement": {
                            "requirement_type": "reference timepoint",
                            "expected_value": "Day 1 Cycle 1"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "8. Patients on stable dose of bisphosphonates or Denosumab, which have been started no less than 4 weeks prior to treatment start, may continue on this medication, however patients are not allowed to initiate bisphosphonate/Denosumab therapy during the DLT-assessment period of the study.",
                "criterions": [
                    {
                        "exact_snippets": "Patients on stable dose of bisphosphonates or Denosumab, which have been started no less than 4 weeks prior to treatment start, may continue on this medication",
                        "criterion": "bisphosphonate or Denosumab therapy",
                        "requirement": {
                            "requirement_type": "dose stability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Patients on stable dose of bisphosphonates or Denosumab, which have been started no less than 4 weeks prior to treatment start, may continue on this medication",
                        "criterion": "bisphosphonate or Denosumab therapy",
                        "requirement": {
                            "requirement_type": "therapy start time before treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "patients are not allowed to initiate bisphosphonate/Denosumab therapy during the DLT-assessment period of the study",
                        "criterion": "bisphosphonate or Denosumab therapy initiation during DLT-assessment period",
                        "requirement": {
                            "requirement_type": "initiation during DLT-assessment period",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Patients on stable dose of bisphosphonates or Denosumab, which have been started no less than 4 weeks prior to treatment start, may continue on this medication",
                                "criterion": "bisphosphonate or Denosumab therapy",
                                "requirement": {
                                    "requirement_type": "dose stability",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Patients on stable dose of bisphosphonates or Denosumab, which have been started no less than 4 weeks prior to treatment start, may continue on this medication",
                                "criterion": "bisphosphonate or Denosumab therapy",
                                "requirement": {
                                    "requirement_type": "therapy start time before treatment",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 4,
                                        "unit": "weeks"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "patients are not allowed to initiate bisphosphonate/Denosumab therapy during the DLT-assessment period of the study",
                        "criterion": "bisphosphonate or Denosumab therapy initiation during DLT-assessment period",
                        "requirement": {
                            "requirement_type": "initiation during DLT-assessment period",
                            "expected_value": false
                        }
                    }
                ]
            }
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "identified_line": {
                "line": "4. Serum creatinine <1.5 x upper limit of normal (ULN) or calculated creatinine clearance ≥ 60 mL/min/1.73 m2 by Cockcroft-Gault",
                "criterions": [
                    {
                        "exact_snippets": "Serum creatinine <1.5 x upper limit of normal (ULN)",
                        "criterion": "serum creatinine",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "calculated creatinine clearance ≥ 60 mL/min/1.73 m2 by Cockcroft-Gault",
                        "criterion": "calculated creatinine clearance",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 60,
                                "unit": "mL/min/1.73 m2"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Serum creatinine <1.5 x upper limit of normal (ULN)",
                        "criterion": "serum creatinine",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "calculated creatinine clearance \u001e 60 mL/min/1.73 m2 by Cockcroft-Gault",
                        "criterion": "calculated creatinine clearance",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 60,
                                "unit": "mL/min/1.73 m2"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "5. Serum total bilirubin <1.5 x ULN (unless due to Gilbert's syndrome in which case direct bilirubin must be normal",
                "criterions": [
                    {
                        "exact_snippets": "Serum total bilirubin <1.5 x ULN",
                        "criterion": "serum total bilirubin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "unless due to Gilbert's syndrome in which case direct bilirubin must be normal",
                        "criterion": "direct bilirubin (in patients with Gilbert's syndrome)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": "normal"
                        }
                    }
                ]
            },
            "logical_structure": {
                "condition": {
                    "exact_snippets": "unless due to Gilbert's syndrome",
                    "criterion": "Gilbert's syndrome",
                    "requirement": {
                        "requirement_type": "presence",
                        "expected_value": true
                    }
                },
                "then_criteria": {
                    "exact_snippets": "unless due to Gilbert's syndrome in which case direct bilirubin must be normal",
                    "criterion": "direct bilirubin (in patients with Gilbert's syndrome)",
                    "requirement": {
                        "requirement_type": "quantity",
                        "expected_value": "normal"
                    }
                },
                "else_criteria": {
                    "exact_snippets": "Serum total bilirubin <1.5 x ULN",
                    "criterion": "serum total bilirubin",
                    "requirement": {
                        "requirement_type": "quantity",
                        "expected_value": {
                            "operator": "<",
                            "value": 1.5,
                            "unit": "x ULN"
                        }
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "1. Histologically or cytologically confirmed adenocarcinoma of prostate",
                "criterions": [
                    {
                        "exact_snippets": "Histologically or cytologically confirmed adenocarcinoma of prostate",
                        "criterion": "adenocarcinoma of prostate",
                        "requirement": {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histologically",
                                "cytologically"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        }
    ],
    "failed_exclusion": [
        {
            "identified_line": {
                "line": "1. Implantation of investigational medical device ≤4 weeks of Cycle 1, Day 1 or current enrollment in oncologic investigational drug or device study",
                "criterions": [
                    {
                        "exact_snippets": "Implantation of investigational medical device ≤4 weeks of Cycle 1, Day 1",
                        "criterion": "implantation of investigational medical device",
                        "requirement": {
                            "requirement_type": "time since implantation",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "current enrollment in oncologic investigational drug or device study",
                        "criterion": "enrollment in oncologic investigational drug or device study",
                        "requirement": {
                            "requirement_type": "current enrollment",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Implantation of investigational medical device \u001e4 weeks of Cycle 1, Day 1",
                        "criterion": "implantation of investigational medical device",
                        "requirement": {
                            "requirement_type": "time since implantation",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "current enrollment in oncologic investigational drug or device study",
                        "criterion": "enrollment in oncologic investigational drug or device study",
                        "requirement": {
                            "requirement_type": "current enrollment",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "10. Currently active other malignancy other than non-melanoma skin cancer. Patients are considered not to have \"currently active\" malignancy if they have completed any necessary therapy and are considered by their physician to be at less than 30% risk of relapse.",
                "criterions": [
                    {
                        "exact_snippets": "Currently active other malignancy other than non-melanoma skin cancer",
                        "criterion": "other malignancy (excluding non-melanoma skin cancer)",
                        "requirement": {
                            "requirement_type": "activity status",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Patients are considered not to have \"currently active\" malignancy if they have completed any necessary therapy",
                        "criterion": "completion of necessary therapy for malignancy",
                        "requirement": {
                            "requirement_type": "completion status",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "considered by their physician to be at less than 30% risk of relapse",
                        "criterion": "risk of malignancy relapse",
                        "requirement": {
                            "requirement_type": "risk percentage",
                            "expected_value": {
                                "operator": "<",
                                "value": 30,
                                "unit": "%"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Currently active other malignancy other than non-melanoma skin cancer",
                                "criterion": "other malignancy (excluding non-melanoma skin cancer)",
                                "requirement": {
                                    "requirement_type": "activity status",
                                    "expected_value": true
                                }
                            },
                            {
                                "or_criteria": [
                                    {
                                        "exact_snippets": "Patients are considered not to have \"currently active\" malignancy if they have completed any necessary therapy",
                                        "criterion": "completion of necessary therapy for malignancy",
                                        "requirement": {
                                            "requirement_type": "completion status",
                                            "expected_value": false
                                        }
                                    },
                                    {
                                        "exact_snippets": "considered by their physician to be at less than 30% risk of relapse",
                                        "criterion": "risk of malignancy relapse",
                                        "requirement": {
                                            "requirement_type": "risk percentage",
                                            "expected_value": {
                                                "operator": ">=",
                                                "value": 30,
                                                "unit": "%"
                                            }
                                        }
                                    }
                                ]
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. Use of investigational drugs ≤4 weeks or <5 half-lives of Cycle 1, Day 1 or current enrollment in investigational oncology drug or device study",
                "criterions": [
                    {
                        "exact_snippets": "Use of investigational drugs ≤4 weeks or <5 half-lives of Cycle 1, Day 1",
                        "criterion": "use of investigational drugs",
                        "requirement": {
                            "requirement_type": "time since last use",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">",
                                        "value": 4,
                                        "unit": "weeks"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 5,
                                        "unit": "half-lives"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "current enrollment in investigational oncology drug or device study",
                        "criterion": "current enrollment in investigational oncology drug or device study",
                        "requirement": {
                            "requirement_type": "enrollment status",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Use of investigational drugs ≤4 weeks or <5 half-lives of Cycle 1, Day 1",
                                "criterion": "use of investigational drugs",
                                "requirement": {
                                    "requirement_type": "time since last use",
                                    "expected_value": {
                                        "comparisons": [
                                            {
                                                "operator": "<=",
                                                "value": 4,
                                                "unit": "weeks"
                                            },
                                            {
                                                "operator": "<",
                                                "value": 5,
                                                "unit": "half-lives"
                                            }
                                        ]
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "current enrollment in investigational oncology drug or device study",
                        "criterion": "current enrollment in investigational oncology drug or device study",
                        "requirement": {
                            "requirement_type": "enrollment status",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "9. Having partners of childbearing potential and not willing to use a method of birth control deemed acceptable by the principle investigator and chairperson during the study and for 1 month after last study drug administration",
                "criterions": [
                    {
                        "exact_snippets": "Having partners of childbearing potential",
                        "criterion": "partners' childbearing potential",
                        "requirement": {
                            "requirement_type": "childbearing potential",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "not willing to use a method of birth control deemed acceptable by the principle investigator and chairperson during the study and for 1 month after last study drug administration",
                        "criterion": "use of acceptable birth control method",
                        "requirement": {
                            "requirement_type": "willingness to use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "not willing to use a method of birth control deemed acceptable by the principle investigator and chairperson during the study and for 1 month after last study drug administration",
                        "criterion": "use of acceptable birth control method",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": [
                                "during the study",
                                "for 1 month after last study drug administration"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "not willing to use a method of birth control deemed acceptable by the principle investigator and chairperson during the study and for 1 month after last study drug administration",
                        "criterion": "use of acceptable birth control method",
                        "requirement": {
                            "requirement_type": "acceptability",
                            "expected_value": "deemed acceptable by the principle investigator and chairperson"
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "6. Other serious illness(es) involving the cardiac, respiratory, CNS, renal, hepatic or hematological organ systems which might preclude completion of this study or interfere with determination of causality of any adverse effects experienced in this study",
                "criterions": [
                    {
                        "exact_snippets": "Other serious illness(es) involving the cardiac, respiratory, CNS, renal, hepatic or hematological organ systems",
                        "criterion": "serious illness involving organ systems",
                        "requirement": {
                            "requirement_type": "organ systems involved",
                            "expected_value": [
                                "cardiac",
                                "respiratory",
                                "CNS",
                                "renal",
                                "hepatic",
                                "hematological"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Other serious illness(es) involving the cardiac, respiratory, CNS, renal, hepatic or hematological organ systems",
                        "criterion": "serious illness involving organ systems",
                        "requirement": {
                            "requirement_type": "seriousness",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "which might preclude completion of this study",
                        "criterion": "potential to preclude study completion",
                        "requirement": {
                            "requirement_type": "potential to preclude study completion",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "interfere with determination of causality of any adverse effects experienced in this study",
                        "criterion": "potential to interfere with causality determination of adverse effects",
                        "requirement": {
                            "requirement_type": "potential to interfere with causality determination",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        }
    ],
    "failed_miscellaneous": []
}